TrialCompass™ TCL
Back to trials
Not yet recruitingPriority 4 · Lower priorityNCT06651203

Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

ClinicalTrials.gov

Plain-language summary

This study is developing and validating improved flow cytometry methods to better detect circulating tumor cells in patients with cutaneous T-cell lymphoma (CTCL) or enteropathy-associated T-cell lymphoma. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Follow-up (OTHER): Clinical evaluation Blood sample Skin biopsy

  • Follow-up

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

NCT06651203

Status: Not yet recruiting | Priority: Lower

Plain-language summary

This study is developing and validating improved flow cytometry methods to better detect circulating tumor cells in patients with cutaneous T-cell lymphoma (CTCL) or enteropathy-associated T-cell lymphoma. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Follow-up (OTHER): Clinical evaluation Blood sample Skin biopsy

Drugs / treatments: Follow-up

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 460 patients

Primary endpoint: Specificity of KIR3DL2 in the diagnosis of Sezary syndrome

Ages: 18 Years to —

Start date: 2024-11-01 | Est. completion: 2029-11-01

Locations

0 US sites · 0 total

Contact

Hélène Moins, MD PhD | helene.moins@u-paris.fr | 142499629

Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)

Tags

CTCL · EATL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06651203

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.